Foley attorneys filed an amicus brief in the United States District Court for the Southern District of New York related to ACLU v. Myriad regarding subject matter patentability of gene patents specifically on isolated DNA. The authors conclude that the U.S. Congress, U.S. courts and the USPTO, as well as the scientific community and biotechnology industry have long relied upon an understanding that claims directed to “isolated DNA” recite patentable subject matter under 35 U.S.C. §101 and the Constitution. The authors maintain that to hold otherwise would have a dramatic negative effect on biotech research as we know it, and will influence the entire business of biotechnology in ways unforeseen or addressed by the plaintiffs in ACLU v. Myriad”
People
Related News
18 December 2024
Press Releases
Foley Names Jen Cafferty Patton as Chief Operating Officer to Further Drive Strategic Growth and Business Performance
Foley & Lardner LLP is pleased to announce Jen Cafferty Patton has been promoted to Chief Operating Officer to bolster the firm’s administrative leadership and advance its strategic priorities.
11 December 2024
Press Releases
Foley Releases Guide to Navigate Issues Stemming from Rapid Expansion of Antibody Drug Conjugates
Foley & Lardner LLP today released Antibody Drug Conjugates Keep Growing: What You Need to Know, a guide that answers many business and legal questions about the rapid expansion of this area of technology.
11 December 2024
Press Releases
Foley Expands East Coast Presence with IP Partner Brian Tomkins, Strengthening Capabilities in Technology and Health Care Sectors
Foley & Lardner LLP announced today that the firm has bolstered its Innovative Technology and Health Care & Life Sciences Sectors with the addition of Brian Tomkins as a partner in the Mechanical & Electromechanical Technologies Practice Group.